Alpha 2.0
Login Register
» Authors » M Amylon

M Amylon

Explore the profile of M Amylon including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 188
Followers 0
Related Specialties
Hematology
Oncology
Pediatrics
Top 10 Co-Authors
J Pullen
M Link
M P Link
W M Crist
Y Ravindranath
A J Carroll
M Borowitz
B Camitta
J Shuster
J H Laver
Published In
Blood
Med Pediatr Oncol
N Engl J Med
J Clin Oncol
Leukemia
Affiliations
Soon will be listed here.
Recent Articles
1.
Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia
Shah S, Taub J, Witt T, Pollock B, Ding B, Moore D, et al.
Br J Haematol . 2001 Jun; 113(3):746-56. PMID: 11380466
The downstream effects of p15 and p16 gene deletions and loss of transcripts on dihydrofolate reductase (DHFR) were examined in 63 B-precursor (BP) acute lymphoblastic leukaemia (ALL) samples. p15 and/or...
2.
High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes
Frankovich J, Donaldson S, Lee Y, Wong R, Amylon M, Verneris M
Biol Blood Marrow Transplant . 2001 Feb; 7(1):49-57. PMID: 11215699
The use of high-dose therapy (HDT) and autologous hematopoietic cell transplantation (AHCT) for children and adolescents with primary refractory and relapsed Hodgkin's disease is increasing. The purpose of this retrospective...
3.
Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report
Laver J, Barredo J, Amylon M, Schwenn M, Kurtzberg J, Camitta B, et al.
Leukemia . 2000 Mar; 14(3):369-73. PMID: 10720128
Contemporary chemotherapy has significantly improved event-free survival among patients with T cell-lineage acute lymphoblastic leukemia (T-ALL). Unlike B-precursor ALL, most investigators are still using cranial radiation (CRT) and are hesitant...
4.
Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials
Bennett C, Stinson T, Lane D, Amylon M, Land V, Laver J
Med Pediatr Oncol . 2000 Feb; 34(2):92-6. PMID: 10657867
Background: Growth factor use has been shown to ameliorate chemotherapy-induced neutropenia, leading to shorter hospital stays and lower use of parenteral antibiotics, two costly areas of cancer treatment. Prior reports...
5.
Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study
Pullen J, Shuster J, Link M, Borowitz M, Amylon M, Carroll A, et al.
Leukemia . 1999 Nov; 13(11):1696-707. PMID: 10557041
T cell acute lymphocytic leukemia (T-ALL) and B-precursor ALL differ significantly in the clinical characteristics of the patients at presentation and in laboratory-defined characteristics of the leukemic cells. We assessed...
6.
Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants
Abdel-Mageed A, Del Rosario M, Longmate J, Ochoa S, Amylon M, Elfenbein G, et al.
Bone Marrow Transplant . 1999 May; 23(9):929-32. PMID: 10338049
Intravenous immunoglobulin has been used after bone marrow transplants to prevent infections and acute graft-versus-host disease. However, the minimum dose required for protection is unknown. This may have significant economic...
7.
Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study
Laver J, Amylon M, Desai S, Link M, Schwenn M, Mahmoud H, et al.
J Clin Oncol . 1998 Feb; 16(2):522-6. PMID: 9469336
Purpose: Contemporary chemotherapy has significantly improved the event-free survival (EFS) among patients with T-cell disease. However, myelosuppression has been a significant adverse effect of this approach. In this study, we...
8.
Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children
Matherly L, Taub J, Wong S, Simpson P, Ekizian R, Buck S, et al.
Blood . 1997 Jul; 90(2):578-89. PMID: 9226157
The relationships between dihydrofolate reductase (DHFR) levels or methotrexate membrane transport and acute lymphoblastic leukemia (ALL) immunophenotype were evaluated on 51 T-cell and 44 B-precursor ALL specimens from 90 pediatric...
9.
Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions
Diccianni M, Batova A, Yu J, Vu T, Pullen J, Amylon M, et al.
Leuk Res . 1997 Jun; 21(6):549-58. PMID: 9279366
p16 Alterations were detected in > 60% of 103 primary T-ALL samples. In paired diagnosis-relapse patient samples, 80% of the relapse samples with p16 deletion were deleted at diagnosis. When...
10.
Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia
ODonnell M, Long G, Parker P, Niland J, Nademanee A, Amylon M, et al.
J Clin Oncol . 1995 Dec; 13(12):2973-9. PMID: 8523063
Purpose: A non-radiation-containing regimen of busulfan and cyclophosphamide (BU/CY) was evaluated for toxicity, relapse, and long-term survival in patients who received allogeneic bone marrow transplantation (BMT) for myelodysplasia (MDS). Patients...